Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Radiation Oncology
•
Thoracic Malignancies
•
Medical Oncology
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Related Questions
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
How does metaplastic thymoma histology impact your decision regarding adjuvant radiation?
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?
